検索
Lipocine Inc
LPCNウォッチリストに追加
2.120USD
+0.010+0.47%
終値 07-31 16:00（ET）15分遅れの株価
15.85M時価総額
損失額直近12ヶ月PER
詳細情報 Lipocine Inc 企業名
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Incの企業情報
企業コードLPCN
会社名Lipocine Inc
上場日Mar 21, 2014
最高経営責任者「CEO」Patel (Mahesh V)
従業員数16
証券種類Ordinary Share
決算期末Mar 21
本社所在地675 S Arapeen Dr Ste 202
都市SALT LAKE CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号84108-1295
電話番号18019947383
ウェブサイトhttps://www.lipocine.com/
企業コードLPCN
上場日Mar 21, 2014
最高経営責任者「CEO」Patel (Mahesh V)
Lipocine Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
よくある質問
Lipocine Incの上位5名の株主は誰ですか？
Lipocine Incの上位5名の株主は以下のとおりです。Mr. John W. Higuchi
Lipocine Inc（LPCN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Lipocine Incの株式を保有している機関は45社あり、保有株式の総市場価値は約2.08Mで、全体の25.27%を占めています。2025Q4と比較して、機関の持ち株は1533872.00増加しています。